Related Experiment Videos
Promising Drugs in Clinical Development To Treat Advanced Colorectal Cancer
P & T : a Peer-Reviewed Journal for Formulary Management
|April 7, 2017
Abstract:
We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.
Insights
New immunotherapies, biosimilars, and molecular-targeted agents are in late-stage development for advanced colorectal cancer patients. These novel treatments offer potential therapeutic options for this challenging disease.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Advanced colorectal cancer presents significant treatment challenges.
- There is a continuous need for novel therapeutic strategies.
Purpose of the Study:
- To review emerging immunotherapies, biosimilars, and molecular-targeted agents for advanced colorectal cancer.
- To highlight treatments in late-stage development.
Main Methods:
- Literature review of ongoing clinical trials and developmental pipelines.
- Focus on agents with demonstrated efficacy in late-stage development.
Main Results:
- Several immunotherapies are progressing through late-stage clinical trials.
- Biosimilars are demonstrating comparable efficacy and safety profiles.
- Molecular-targeted agents are showing promise for specific patient subgroups.
Conclusions:
- Late-stage development pipelines offer promising new options for advanced colorectal cancer.
- These novel agents, including immunotherapies and targeted therapies, are expected to expand treatment paradigms.